Ole Bitsch-Jensen

2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark.

Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark.

Helion Biotech ApS develops and manufactures drugs. It develops a recombinant human protein from the innate immune system (MASP-2) for therapeutic use in cancer. The firm's MASP-2 protein is used to prevent or treat infectious episodes in MASP-2 deficient patients undergoing chemotherapy. The company was founded by Jeppe Vesti Christensen, Per Bo Pedersen Fischer, Jens Christian Jensenius and Steffen Thiel in 2008 and is headquartered in Lyngby, Denmark.

Mirrx Therapeutics A/S provides protein production technology. Its technology Blockmirs, is steric antisense blockers that bind to specific microRNA binding sites in target RNAs to thereby prevent microRNA binding to the same site. The company was founded by Hans Thorleif Møller on July 1, 2009 and is headquartered in Vejle, Denmark.

FluimediX ApS provides diagnostic system capable of deoxyribonucleic acid based species determination. Its product, called NanoCycler, delivers an identification of the presence of patogen species, based on their unique DNA 'fingerprint'. The firm markets its product for the use of the dairy production industry. It also collaborates with others in the fields of engineering, microtechnology, and surface analysis. The company was founded by Tomas Ussing in 2003 and is headquartered in Taastrup, Denmark.

Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark.

CytoTrack ApS engages in the provision of medical scanners for rare cell detection systems. Its products include CytoTrack CT11 scanner, CytoDisk and CytoCover, and CytoTrack reagent kit. The company was founded by Christian Caspersen, Tom Hede Markussen and Lars Ulrik Nielsen in 2004 and is headquartered in Lyngby, Denmark.

Pharma 2100 ApS engages in the research and development of pharmaceutical products. It conducts research on medical drugs to obtain patents and possible productions of these drugs. The company was founded on January 1, 2002 and is headquartered in Vanløse, Denmark.

SEED Capital Management I/S is an Independent Venture Capital firm founded in 2004. The company is headquartered in Copenhagen, Denmark.